The effects of intravenous morphine sulfate with ketamine in renal pain.

A Comparison, between the analgesic effects of intravenous morphine sulfate with ketamine regimen, and intravenous morphine sulfate regimen solely,in management of the acute pain in renal colic patients who admitted to the emergency department of Imam Khomeini hospital of Sari in year 1394

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015080523517N1

Enrollment

200

Registered

2017-04-15

Start date

2015-09-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal colic. Unspecified renal colic

Interventions

Intervention 1: Morphine sulfate with 0.1 mg / kg the time of intervention and if necessary 0.05 mg / kg in 20 minute after intervention in both control and experimental groups. Intervention 2: Ketami

Treatment - Drugs

Morphine sulfate with 0.1 mg / kg the time of intervention and if necessary 0.05 mg / kg in 20 minute after intervention in both control and experimental groups

Ketamine 0.2 mg/kg before the time of intervention in experimental group

Placebo(normal salin) 5 ml at the time of intervention in control group

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: All patients with acute renal colic with VAS pain score between 7 and 10. Exclusion criteria: Pregnancy or probable pregnancy; Breast feeding; Contraindications for Morphine usage; History of opium addiction; Taking any analgesics during last 6 hours prior of admission; Peritoneal signs and symptoms in abdominal examination; History of cardiovascular diseases; Psychosis; Refusal of the patients from the participation.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Visual analogue scale.	—

Secondary

Measure	Time frame
Respiratory rate. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Respiratory rate in minute.;Nausea. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/negative.;Vomiting. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/negative.;Vertigo. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/ negative.;Blood pressure. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: mmHg.;Rash or hives. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/ negative.	—

Measure

Time frame

Respiratory rate. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Respiratory rate in minute.;Nausea. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/negative.;Vomiting. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/negative.;Vertigo. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/ negative.;Blood pressure. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: mmHg.;Rash or hives. Timepoint: Zero, 20 and 40 minute after intervention. Method of measurement: Positive/ negative.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSalman Erfanian Irankar

Mazandaran University of Medical Sciences

s.erfanian@mazums.ac.ir+98 11 3336 1700

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026